Joseph A Odin, MD, PhD Email Joseph Odin
- PROFESSOR | Medicine, Liver Diseases
- Liver Medicine
- Liver Transplantation
- Hospital Affiliation
- The Mount Sinai Hospital
Dr. Odin is an associate professor in the Division of Liver Diseases and the Recanati/Miller Transplantation Institute with a clinical background in gastroenterology and liver disease. He is co-director of the Mount Sinai Autoimmune Liver Disease Program. He has research interest in liver autoimmunity and toxicology. His current research studies are focused on novel treatments for primary biliary cirrhosis, primary sclerosing cholangitis and the effect of drugs and toxins on the liver. He cares for individuals with all liver diseases including those with liver transplants. His research is supported by the NIH and he has received past support and awards from the American Gastroenterolofical Association and the American Association for the Study of Liver Disease. He also receives support from pharmaceutical companies for participation in clinical trials examining treatments for viral hepatitis.
Dr. Odin was recently designated as a Fellow of the American Association for the Study of Liver Diseases (FAASLD) — the highest honor among AASLD membership categories — which recognizes superior professional achievement in clinical or academic practice, and in basic or clinical research.
RMTI Website: www.MountSinaiRMTI.org
Autoimmune Liver Disease Treatment Program
- Endoscopic Band Ligation
- Esophageal Varices
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Liver Biopsy
- Liver Transplant
- Toxic Hepatitis
- Upper GI Endoscopy
- Wilson's Disease
AB, Cornell University
MD, Mount Sinai Sch. of Medicine CUNY
Residency, Internal Medicine
Mount Sinai Hospital
Johns Hopkins Hospital
Solomon Silver Award for Clinical Research
Research Excellence in GI and Liver Disease Award
Dr. Odin's liver research focuses on Autoimmune Liver Disease, Toxicity, Fatty Liver Disease, and Viral Hepatitis. Clinical trials and studies are being conducted or planned for primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, drug or toxin induced liver injury, hepatitis B and C, and non-alcoholic fatty liver disease. Some of the research is investigator initiated while other studies are supported by the National Institutes of Health or Pharmaceutical Companies. Please go to Programs in Autoimmune Liver Diseases.
An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)
The purpose of this study is to compare the effectiveness and safety of MBX-8025 on Primary Biliary Cirrhosis (PBC) when available treatment with UDCA has proved inadequate or not tolerated. This will be assessed by looking at how the drug affects Primary Biliary Cirrhosis (PBC)....
A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis Patients Who Are Refractory or Intolerant to Current Therapies
The purpose of this study is to test the safety and effectiveness of JKB-122 (the study drug) for treatment of Autoimmune Hepatitis (AIH). JKB-122 is a compound that blocks the formation of chemicals in the body that produce inflammation that can lead to liver disease. Subject...
A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis (EPICS )
This is a Phase 2 prospective, multicenter, randomized, double-blind, placebo-controlled study planned to enroll a total of 36 patients from 10-12 sites with a diagnosis of Primary Biliary Cholangitis (PBC) who meet the study's inclusion/exclusion criteria. The purpose of this...
Hirschfield GM, Liu X, Han Y, Gorlov IP, Lu Y, Xu C, Lu Y, Chen W, Juran BD, Coltescu C, Mason AL, Milkiewicz P, Myers RP, Odin JA, Luketic VA, Speiciene D, Vincent C, Levy C, Gregersen PK, Zhang J, Heathcote EJ, Lazaridis KN, Amos CI, Siminovitch KA. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nature genetics 2010 Aug; 42(8).
Singal AK, Stanca CM, Clark V, Dixon L, Levy C, Odin JA, Fiel MI, Friedman SL, Bach N. Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature. Hepatology international 2011 Sep; 5(3).
Allina J, Grabowski J, Doherty-Lyons S, Fiel MI, Jackson CE, Zelikoff JT, Odin JA. Maternal allergy acts synergistically with cigarette smoke exposure during pregnancy to induce hepatic fibrosis in adult male offspring. Journal of immunotoxicology; 8(4).
Hirschfield GM, Xie G, Lu E, Sun Y, Juran BD, Chellappa V, Coltescu C, Mason AL, Milkiewicz P, Myers RP, Odin JA, Luketic VA, Bacon B, Bodenheimer H, Liakina V, Vincent C, Levy C, Pillai S, Lazaridis KN, Amos CI, Siminovitch KA. Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes and immunity 2012 Jun; 13(4).
Hu B, Allina J, Bai J, Kesar V, Odin JA. Catalase and estradiol inhibit mitochondrial protein S-glutathionylation. Molecular and cellular biochemistry 2012 Aug; 367(1-2).
Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, Kosoy R, Ransom M, Sun Y, Bianchi I, Schlicht EM, Lleo A, Coltescu C, Bernuzzi F, Podda M, Lammert C, Shigeta R, Chan LL, Balschun T, Marconi M, Cusi D, Heathcote EJ, Mason AL, Myers RP, Milkiewicz P, Odin JA, Luketic VA, Bacon BR, Bodenheimer HC, Liakina V, Vincent C, Levy C, Franke A, Gregersen PK, Bossa F, Gershwin ME, deAndrade M, Amos CI, Lazaridis KN, Seldin MF, Siminovitch KA. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Human molecular genetics 2012 Dec; 21(23).
Torres J, Bao X, Iuga AC, Chen A, Harpaz N, Ullman T, Cohen BL, Pineton de Chambrun G, Asciutti S, Odin JA, Sachar DB, Gaskins HR, Setchell K, Colombel JF, Itzkowitz SH. Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia. Inflammatory bowel diseases 2013 Feb; 19(2).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Odin during 2017 and/or 2018. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Intercept Pharmaceuticals Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.